ArticleJournal of cellular and molecular medicine2025
CXCL1 Promotes Osteoblast Autophagy and Inhibits Ferroptosis Through the Activation of the TGF-β/Smad Signalling Pathway.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Diosgenin presents a novel role in promoting diabetic wound healing: A mechanism involving Sirt6/Nrf2-mediated inhibition of ferroptosis.Journal of pharmaceutical analysis · 2026Article
- Integrating Single-Cell and Microarray Data to Explore the Role of Autophagy-Related Gene Atg7 in Osteoporosis.Journal of inflammation research · 2026Article
- CXCL1 Promotes Osteoblast Autophagy and Inhibits Ferroptosis Through the Activation of the TGF-β/Smad Signalling Pathway.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Osteoblast dysfunction plays a central role in osteoporosis. CXC chemokine ligand 1 (CXCL1), a known inflammatory mediator, is increasingly recognised for its role in bone homeostasis. However, its influence on osteoblast survival mechanisms such as ferroptosis and autophagy remains unclear. This study explores the role of CXCL1 in promoting osteoblast differentiation and activity by inhibiting ferroptosis and enhancing autophagy via the TGF-β/Smad signalling pathway. Primary rat osteoblasts were treated with recombinant CXCL1, shRNA constructs and pathway modulators, such as Galunisertib, Fer-1 and Chloroquine (CQ). Osteoblast differentiation, autophagy, ferroptosis and TGF-β/Smad pathway activity were evaluated using qPCR, western blotting, staining and densitometric analysis. CXCL1 knockdown impaired osteoblast proliferation and differentiation, while increasing intracellular iron and ROS and enhancing ACSL4 expression, indicative of ferroptosis. These effects were partially reversed by Fer-1. Besides, CXCL1 activated the TGF-β/Smad signalling cascade, and Galunisertib inhibited this signalling and partially suppressed CXCL1-induced effects. Furthermore, CXCL1 promoted autophagy via increased Beclin-1 and LC3B and reduced p62, which mitigated ferroptosis and supported osteogenesis. Our findings suggest that CXCL1 promotes osteoblast differentiation by inhibiting ferroptosis and enhancing autophagy through activation of the TGF-β/Smad signalling pathway. Collectively, our results highlight CXCL1 as a promising therapeutic target for osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.